Belite Bio, Inc.(BLTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BLTE Belite Bio, Inc.

Pre-Mkt 01-06 05:13:42 EST

159.42

+0.15

+0.09%

High160.50	Low153.56	Vol199.03K
Open159.17	D1 Closing159.27	Amplitude4.36%
Mkt Cap5.98B	Tradable Cap3.18B	Total Shares37.51M
T/O31.44M	T/O Rate1.00%	Tradable Shares19.96M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BLTE","market":"US","secType":"STK","nameCN":"Belite Bio, Inc.","latestPrice":159.42,"timestamp":1767646800000,"preClose":159.27,"halted":0,"volume":199032,"delay":0,"floatShares":19963600,"shares":37514630,"eps":-1.929025,"marketStatus":"Pre-Mkt","change":0.15,"latestTime":"01-06 05:13:42 EST","open":159.165,"high":160.5,"low":153.56,"amount":31440557.605200004,"amplitude":0.043574,"askPrice":169.71,"askSize":100,"bidPrice":143.9,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.929025,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1767709800000},"marketStatusCode":1,"adr":0,"adrRate":1,"listingDate":1651204800000,"exchange":"NASDAQ","adjPreClose":159.42,"postHourTrading":{"tag":"盘后","latestPrice":159.42,"preClose":159.42,"latestTime":"17:10 EST","volume":18338,"amount":2923446.28,"timestamp":1767651034606},"volumeRatio":1.1337624611602855},"requestUrl":"/m/hq/s/BLTE","defaultTab":"news","newsList":[{"id":"2588204373","title":"Belite Bio Inc : Benchmark Raises Target Price to $187 From $132","url":"https://stock-news.laohu8.com/highlight/detail?id=2588204373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588204373?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:03","pubTimestamp":1764763391,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X90MW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2588015746","title":"U.S. RESEARCH ROUNDUP-Crowdstrike, CSW Industrials, Targa Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2588015746","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588015746?lang=en_us&edition=fundamental","pubTime":"2025-12-03 16:02","pubTimestamp":1764748965,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Crowdstrike, CSW Industrials, Targa ResourcesDec 3 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nL4N3X90IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1069344957.HKD","CPRT","LU1815336760.USD","IE00B19Z9505.USD","LU0056508442.USD","LU2360108059.USD","SG9999000418.SGD","TRGP","BK4551","LU0154236417.USD","LU2087625088.SGD","OKTA","IE00BN8TJ469.HKD","ASAN","CGNX","LU0498741890.SGD","MSBI","GTLB","LU0642271901.SGD","LU1992135472.HKD","LU0154245673.USD","SGXZ99366536.SGD","CSW","BLTE","LU1169590202.USD","BK4608","AU","BK4177","BK4007","PSTG","SGXZ51526630.SGD","LU1989764664.SGD","LU0323240290.USD","BK4515","MNST","BK4528","LU0353189763.USD","LU0719512351.SGD","LU0786609619.USD","BROS","LU1989764748.USD","LU2106854487.HKD","AEO","CRWD","LU1548497426.USD","LU0097036916.USD","BK4094","BK4116"],"gpt_icon":1},{"id":"2588309400","title":"Belite Bio Inc : Maxim Group Raises Target Price to $200 From $140","url":"https://stock-news.laohu8.com/highlight/detail?id=2588309400","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588309400?lang=en_us&edition=fundamental","pubTime":"2025-12-03 13:00","pubTimestamp":1764738056,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X811S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2588495057","title":"Belite's Tinlarebant Results Boost Wall Street Confidence -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2588495057","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588495057?lang=en_us&edition=fundamental","pubTime":"2025-12-03 00:44","pubTimestamp":1764693840,"startTime":"0","endTime":"0","summary":"1144 ET - Belite Bio's encouraging results from its Phase 3 trial of Tinlarebant, an eye disease drug, are boosting Wall Street confidence in the San Diego-based pharmaceutical company. Both Cantor and Mizuho raised their price targets, with Mizuho upgrading the stock to outperform.Mizuho's Graig Suvannavejh writes that despite concerns about Belite's prior supportive data for Tinlarebant, the positive results and substantial peak market for the drug -- $4.2 billion, he estimates -- are fortuitous for the company. \"In light of the robustness we saw in yesterday's data, we now come around on tinlarebant ,\" he writes. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2588205296","title":"BUZZ-U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Cloudflare, Boeing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588205296","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588205296?lang=en_us&edition=fundamental","pubTime":"2025-12-02 23:54","pubTimestamp":1764690867,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Cloudflare, BoeingEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nL6N3X80UZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4543","TER","BLTE","CBRE","IE00BFXG1179.USD","NET","EB","CDE","BK4210","BK4606","LU0456854461.SGD","LU1861220033.SGD","LU1496350502.SGD","BA","BG","BMY","IE00BJJMRZ35.SGD","BLKB","BK4532","LU0061475181.USD","WBD","FUN","EXC","ATO","LU1670710661.SGD","SIG","PPSI","LU1496350171.SGD","LU0130517989.USD","CF","BK4079","LU1861215975.USD","LU0345780281.USD","BK4093","LU1670710588.SGD","AMRX","LU1815336760.USD","LU0154245756.USD","HL","LU1670711040.USD","LU2065170008.USD","LU0345781412.USD","LU1670711123.USD","SGMO","JANX","LU2290526834.HKD","CTRN"],"gpt_icon":1},{"id":"2588059606","title":"BUZZ-Belite Bio eyes fresh record after $350 mln equity raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2588059606","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588059606?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:17","pubTimestamp":1764685052,"startTime":"0","endTime":"0","summary":"** Belite Bio's BLTE.O shares up 3.9% premarket to $160 after overnight $350 mln follow-on priced. ** Drug developer late Mon said it sold ~2.3 mln American Depositary Shares at $154. ** BLTE shares on Mon hit intraday record high of $154.99 and finished session up 12% at $154.02 after co's experimental drug for a rare genetic eye disease met main goal in late-stage study. ** Co intends to use net offering proceeds for commercialization preparation and developing its pipelines, and for working capital and other general purposes** Morgan Stanley, Leerink, BofA and Cantor Fitzgerald are joint bookrunners** BLTE has ~35.2 mln shares outstanding as of Nov 30, per the offering prospectus** Separately, Mizuho upgrades BLTE to 'outperform' from 'neutral' and boosts PT to $194  in reaction to the eye disease drug news** Now, all 6 brokerages covering BLTE are bullish and their median PT is $140, per LSEG data** Through Mon close, BLTE shares surged 144% over the past three months","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nL6N3X80RT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1732800096.USD","LU0267386448.USD","BK4007","LU0882574139.USD","LU0971096721.USD","BK4588","LU0557290698.USD","LU1668664300.SGD","LU0314104364.USD","LU1244550494.USD","LU1244550577.SGD","LU1548497426.USD","LU1720051017.SGD","BK4534","LU1791710582.SGD","BK4516","LU2133065610.SGD","LU1162221912.USD","BK4127","LU1074936037.SGD","IE00BZ1G4Q59.USD","LU0106261372.USD","LU0098860793.USD","LU1720051108.HKD","BK4504","LU2089283258.USD","LU0225283273.USD","LU0795875086.SGD","LU1989772840.SGD","LU2028103732.USD","LU2023251221.USD","LU2347655156.SGD","LU2357305700.SGD","LU0912757837.SGD","LU0528227936.USD","BK4585","IE00BKVL7J92.USD","LU2089284900.SGD","LU1244550221.USD","LU2111349929.HKD","BLTE","BK4581","LU0234570918.USD","LU1732799900.SGD","LU0006306889.USD","LU0795875169.SGD","LU0320765646.SGD","LU0106831901.USD","LU2271345857.HKD","LU1791710400.SGD"],"gpt_icon":0},{"id":"2588031619","title":"Belite Bio Inc : Mizuho Raises to Outperform From Neutral; Raises Target Price to $194 From $105","url":"https://stock-news.laohu8.com/highlight/detail?id=2588031619","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588031619?lang=en_us&edition=fundamental","pubTime":"2025-12-02 18:05","pubTimestamp":1764669936,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80CA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2588036257","title":"Belite Bio Prices $350 Million Equity Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2588036257","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588036257?lang=en_us&edition=fundamental","pubTime":"2025-12-02 17:32","pubTimestamp":1764667976,"startTime":"0","endTime":"0","summary":"Belite Bio  said Monday it has priced an underwritten public offering of about 2.3 million American depositary shares at $154 each.The company said it has also granted underwriters a 30-day option to purchase up to 340,909 additional depositary shares.The company said it expects gross proceeds of about $350 million from the offering, which is expected to close about Wednesday.The company said it plans to use net proceeds of the offering for general corporate purposes.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4585","EQR","BLTE","BK4007","BK4215"],"gpt_icon":0},{"id":"2588855750","title":"Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588855750","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588855750?lang=en_us&edition=fundamental","pubTime":"2025-12-02 11:37","pubTimestamp":1764646636,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X70TI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2588055457","title":"Belite Bio Inc. reports nine-month 2025 general and administrative expenses of USD 25.4 million, up over 3 times","url":"https://stock-news.laohu8.com/highlight/detail?id=2588055457","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588055457?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:54","pubTimestamp":1764626059,"startTime":"0","endTime":"0","summary":"Belite Bio Inc. reported its financial results for the nine months ended September 30, 2025. The company recorded a net loss of USD 52.3 million, compared to a net loss of USD 26.0 million for the same period in the previous year. Total operating expenses reached USD 56.1 million for the period, primarily driven by research and development expenses of USD 30.8 million and general and administrative expenses of USD 25.4 million. Interest income, net, was USD 3.5 million. As of September 30, 2025, Belite Bio Inc. had cash and cash equivalents of USD 157.0 million, short-term investments of USD 118.6 million, and working capital of USD 269.1 million. The company's accumulated deficit stood at USD 159.9 million at the end of the period. Net loss per ordinary share for the nine-month period was USD 1.60.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL9b0VYx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"2588670367","title":"Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588670367","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588670367?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:20","pubTimestamp":1764624000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Dec.  01, 2025  (GLOBE NEWSWIRE) -- Belite Bio, Inc(NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3197471/0/en/Belite-Bio-Announces-Proposed-Underwritten-Public-Offering-of-American-Depositary-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1363072403.SGD","LU2054465674.USD","IE00BMPRXN33.USD","LU0081259029.USD","LU0882574139.USD","LU1923623000.USD","IE00BMPRXR70.SGD","LU2355687059.USD","BK4612","LU0889565833.HKD","IE0009356076.USD","LU0109392836.USD","LU1803068979.SGD","LU2271345857.HKD","IE00BZ1G4Q59.USD","BK4543","LU0642271901.SGD","LU0823421416.USD","LU0098860793.USD","AFG","LU0823434583.USD","LU1548497426.USD","LU2347655156.SGD","LU0158827948.USD","LU1162221912.USD","BK4107","BK4588","LU1988902786.USD","LU1989764664.SGD","LU0198837287.USD","LU1074936037.SGD","BK4141","LU0823421333.USD","LU1951198990.SGD","LU1720051017.SGD","LU2357305700.SGD","LU0314104364.USD","BLTE","LU0320765646.SGD","LU1732799900.SGD","LU1732800096.USD","LU0274383776.USD","LU0719512351.SGD","BK4504","BK4573","LU1244550577.SGD","IE00B5949003.HKD","BK4566","BK4605"],"gpt_icon":1},{"id":"2588377769","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2588377769","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588377769?lang=en_us&edition=fundamental","pubTime":"2025-12-02 02:32","pubTimestamp":1764613968,"startTime":"0","endTime":"0","summary":"Q32 Bio's  shares doubled amid heavy trading after the company said Monday it sold alopecia areata drug candidate ADX-097 to Akebia Therapeutics .More than 157.3 million shares of Q32 Bio traded intraday compared with a daily average of about 223,000.Kala Bio  said Monday it has entered into a $6 million securities purchase agreement with private investor David E. Lazar for the purchase of the company's non-voting convertible preferred stock.Effective immediately, Lazar has been appointed Kala's chief executive officer and chairman. Former CEO Todd Bazemore continues to serve on the board.Shares surged 58% as intraday trading volume catapulted to over 147.5 million from a daily average of about 1.7 million.Belite Bio  said Monday its phase 3 trial of Tinlarebant to treat Stargardt disease type 1 met its primary efficacy endpoint.Shares advanced 8.4% as intraday trading volume climbed to more than 611,000 from a daily average of about 90,000.Price: 4.40, Change: +2.21, Percent Change: +","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","QTTB","BK4139","BLTE","KALA","AKBA"],"gpt_icon":0},{"id":"2588777304","title":"Belite Bio Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2588777304","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588777304?lang=en_us&edition=fundamental","pubTime":"2025-12-02 02:24","pubTimestamp":1764613440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BLTE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 01, 2025 13:24 ET (18:24 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"2588774604","title":"BUZZ-U.S. STOCKS ON THE MOVE-Ideaya Biosciences, Omnicom Group, Targa Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2588774604","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588774604?lang=en_us&edition=fundamental","pubTime":"2025-12-02 00:53","pubTimestamp":1764607982,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Ideaya Biosciences, Omnicom Group, Targa ResourcesEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nL6N3X70KP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACN","NVAX","MRNA","CLNE","FANG","QTTB","TRGP","PAVS","LUV","TSYW.SI","LEG","HL","KGS","AHMA","NVDD","NVDS","OMC","SNPS","IDA","AAL","ZS","INR","FCEL","UAL","DARE","ALT","CDE","FLYE","IDYA","NVDY","NVDU","EXC","ODFL","CPNG","USAC","BLTE"],"gpt_icon":1},{"id":"2588877372","title":"Sector Update: Health Care Stocks Decline Pre-Bell Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2588877372","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588877372?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:18","pubTimestamp":1764598734,"startTime":"0","endTime":"0","summary":"Health care stocks were declining pre-bell Monday, with the Health Care Select Sector SPDR Fund  0.3% lower and the iShares Biotechnology ETF  down 0.6%.Belite Bio  shares were up more than 11% after the company said a phase 3 trial of Tinlarebant to treat Stargardt disease type 1 met its primary efficacy endpoint.Kestra Medical Technologies  stock was down more than 3% after the company reported a wider preliminary fiscal Q2 operating loss.IDEAYA Biosciences  shares were up more than 5% after the company said it has received clearance from the US Food and Drug Administration for an investigational new drug application to begin a Phase 1 trial of IDE034.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","XBI","BK4139","XLV","KMTS","IBB","IDYA","BK4082","BLTE","BK4581","BK4007","LABU"],"gpt_icon":0},{"id":"2588777382","title":"Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Ahead of Manufacturing Reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2588777382","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588777382?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:57","pubTimestamp":1764597463,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.7% and the actively traded Invesco QQQ Trust (QQQ) was 1% lower in Monday's premarket activity, ahead of reports on manufa","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XLP","USO","IYJ","IGM","XLV","MU","UNG","SPY","XSD","VHT.AU","GLD","SOXX","RTH","IWM","BLTE","EETH","IBB","PMR","ARES","IVV","VIS","XLE","BITO","FAZ","RTH.AU","XLF","SPY.AU","XRT","BETH","LEU","XLK","IGV","EQR","HAFN","IYH","VHT","EEM","XLY","IYK",".IXIC","EXI","TSLA","IPK","QQQ","XLI","IYW","IYE","VDC","FAS","SLV"],"gpt_icon":0},{"id":"2588119727","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2588119727","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588119727?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:45","pubTimestamp":1764593159,"startTime":"0","endTime":"0","summary":"Q32 Bio  shares were 71% higher pre-bell Monday after the company said it has sold alopecia areata drug candidate ADX-097 to Akebia Therapeutics .Belite Bio  stock was up 17% after the company said that a late-stage trial of Tinlarebant to treat Stargardt eye disease met its primary efficacy endpoint.Canadian Solar  shares were 13% higher after the company said it will resume direct oversight of its US operations.INVO Fertility  stock was up 12% after the company said it plans to acquire fertility clinic Family Beginnings.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","AKBA","BK4519","IVF","BK4082","QTTB","BK4585","BK4141","BLTE","BK4526","BK4588","BK4007"],"gpt_icon":1},{"id":"2588247667","title":"Belite Bio Says Eye Disease Treatment Trial Meets Primary Efficacy Endpoint; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2588247667","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588247667?lang=en_us&edition=fundamental","pubTime":"2025-12-01 19:59","pubTimestamp":1764590362,"startTime":"0","endTime":"0","summary":"Belite Bio (BLTE) said Monday that a phase 3 trial of Tinlarebant to treat Stargardt disease type 1 met its primary efficacy endpoint.Results showed a \"statistically significant\" reduction in lesion g","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"2588072146","title":"BRIEF-Belite Bio Announces Positive Topline Results From Pivotal Global, Phase 3 Dragon Trial Of Tinlarebant","url":"https://stock-news.laohu8.com/highlight/detail?id=2588072146","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588072146?lang=en_us&edition=fundamental","pubTime":"2025-12-01 19:26","pubTimestamp":1764588418,"startTime":"0","endTime":"0","summary":"BRIEF-Belite Bio Announces Positive Topline Results From Pivotal Global, Phase 3 Dragon Trial Of TinlarebantDec 1 (Reuters) - Belite Bio Inc BLTE.O:NEW HOPE FOR PEOPLE LIVING WITH A DISEASE ONCE DEEME","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA7C5CLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"2588721344","title":"Belite Bio's drug for genetic eye disease meets main goal in late-stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2588721344","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588721344?lang=en_us&edition=fundamental","pubTime":"2025-12-01 19:08","pubTimestamp":1764587298,"startTime":"0","endTime":"0","summary":"Belite Bio's drug for genetic eye disease meets main goal in late-stage trial Dec 1 (Reuters) - Belite Bio BLTE.O said on Monday that its experimental drug for a rare genetic eye disease met the main ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nL4N3X70T5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://investors.belitebio.com","stockEarnings":[{"period":"1week","weight":-0.0355},{"period":"1month","weight":0.0628},{"period":"3month","weight":1.0597},{"period":"6month","weight":1.4847},{"period":"1year","weight":1.5676},{"period":"ytd","weight":-0.0034}],"compareEarnings":[{"period":"1week","weight":-0.0002},{"period":"1month","weight":0.003},{"period":"3month","weight":0.0278},{"period":"6month","weight":0.102},{"period":"1year","weight":0.1618},{"period":"ytd","weight":0.0085}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.035684},{"month":2,"riseRate":0.666667,"avgChangeRate":0.052618},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.036455},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.0153},{"month":5,"riseRate":0.75,"avgChangeRate":0.064631},{"month":6,"riseRate":0.25,"avgChangeRate":0.187208},{"month":7,"riseRate":1,"avgChangeRate":0.228556},{"month":8,"riseRate":0.25,"avgChangeRate":0.09699},{"month":9,"riseRate":0.5,"avgChangeRate":0.027284},{"month":10,"riseRate":0.75,"avgChangeRate":0.224047},{"month":11,"riseRate":0.75,"avgChangeRate":0.12408},{"month":12,"riseRate":0.5,"avgChangeRate":0.042173}],"exchange":"NASDAQ","name":"Belite Bio, Inc.","nameEN":"Belite Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Belite Bio, Inc.(BLTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Belite Bio, Inc.(BLTE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Belite Bio, Inc.,BLTE,Belite Bio, Inc.股票,Belite Bio, Inc.股票老虎,Belite Bio, Inc.股票老虎国际,Belite Bio, Inc.行情,Belite Bio, Inc.股票行情,Belite Bio, Inc.股价,Belite Bio, Inc.股市,Belite Bio, Inc.股票价格,Belite Bio, Inc.股票交易,Belite Bio, Inc.股票购买,Belite Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Belite Bio, Inc.(BLTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Belite Bio, Inc.(BLTE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}